ArticleLipids in health and disease2025
A LASSO-derived model for the prediction of nonattainment of target LDL-C reduction with PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Super learner model for predicting carotid plaque regression in type 2 diabetes on PCSK9 inhibitors.Acta diabetologica · 2026Article
- Comparing burden of ischemic stroke caused by high low-density lipoprotein cholesterol in global and China: trends and projections.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have demonstrated significant efficacy in lowering low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease (ASCVD), but some fail to achieve the target levels. This study aimed to explore the potential risk factors associated with this nonattainment of target LDL-C reduction (NTR-LDLC) and develop a prediction model.
methodsThe population was randomly divided into derivation and verification subsets in a 7:3 ratio. Utilizing the Least Absolute Shrinkage and Selection Operator (LASSO) regression, we filtered the variables within the derivation set. Subsequently, we assessed the model's predictive accuracy for the NTR-LDLC in both subsets through the application of decision curve analysis (DCA) and the plotting of receiver operating characteristic (ROC) curves.
resultsThe study enrolled 748 patients, with 115 individuals experiencing NTR-LDLC. Using LASSO regression, five significant predictive factors associated with NTR-LDLC were identified: statin therapy, diastolic blood pressure (DBP), alanine aminotransferase (ALT), total cholesterol (TC), and LDL-C. Based on these results, a nomogram prediction model was constructed and validated, showing predictive accuracy with the area under the ROC curve (AUC) of 0.718 (95% confidence interval [CI]: 0.657 - 0.779) and 0.703 (95% CI: 0.605 - 0.801) for the derivation and validation sets, respectively.
conclusionsThis study presents a LASSO-derived predictive model that can be used to predict the risk of NTR-LDLC with PCSK9 inhibitors in patients with ASCVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.